SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the focal point, with traders watching guidance, subscriber engagement, advertising growth, and content strategy amid leadership changes and layoffs. Bearish concerns about competition, content quality, and slowing growth contrast with bullish hopes that low expectations and ad expansion could support a positive reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is drawing attention as traders position around the full Phase 3 melanoma cancer-vaccine data presentation at ESMO, following previously reported positive topline results. Bulls see the readout as validation of the oncology pipeline, while skeptics warn that expectations and valuation are elevated and debate whether the event could prompt profit-taking.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is drawing attention, with traders attributing the move to possible short covering and technical buying rather than a confirmed new company announcement. The broader debate centers on upcoming DM1 and FSHD siRNA data: Novartis/Aviditys DM1 trial failure raised concerns about whether target knockdown can translate into patient benefit, while some traders argue Sareptas distinct delivery approach and the loss of a competitor could be favorable.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are falling amid concern over plans to list its Monee financial-services arm and launch Sea Cloud, which traders worry could add spending and strategic uncertainty. The community is split between viewing a Monee separation as a potential value unlock and fearing it could weaken the remaining business, while some see the selloff as an overreaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings beat and a new buyback authorization, as traders focus on narrowed full-year profit guidance with an unchanged midpoint and weaker vehicle sales. Some view the drop as overdone given the stronger cash-flow outlook and buyback, while others see the outlook as too cautious to offset the earnings-day disappointment.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook drew attention as shares sold off despite strong demand, with traders frustrated by the reaction. The debate centers on whether higher costs, weaker cash generation and an insurance loss outweigh the stronger orders and guidance.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside new BRIUMVI data. Traders are hopeful azer-cel could add a growth opportunity beyond BRIUMVI, while recognizing the early readouts efficacy is uncertain; continued BRIUMVI sales growth is the more established part of the story.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers push to a fresh 52-week high is drawing attention, with traders celebrating a long-awaited recovery and debating whether the breakout can hold or will meet resistance. Some point to defensive-sector demand and pipeline progress, while others say the move needs a clearer company-specific catalyst.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention to the drugs potential and analyst optimism. Traders are debating whether the placebo-adjusted benefit is modest and whether agitation concerns and higher discontinuations could limit the upside, with some viewing the move as vulnerable to a fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a balance-sheet and strategic boost. Others question the deal because the divested unit contributes revenue, raising concerns about debt and the outlook for the remaining business; some traders are also taking profits after the surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SoundHound's Q2 Revenues Soar 10X Since 2022: How Much Runway Is Left?

SOUN's Q2 2026 revenues surge nearly 10X from 2022 levels, fueled by enterprise AI demand. Can acquisitions sustain growth despite profitability challenges?

Nice (NICE) Beats Stock Market Upswing: What Investors Need to Know

Nice (NICE) closed at $113.84 in the latest trading session, marking a +1.49% move from the prior day.

SoundHound Stock Trades at a Discount: A Bargain or a Warning Sign?

Is SOUN's 51.1% stock plunge and discounted valuation a buying opportunity, or do persistent losses, cash burn and acquisition risks signal more trouble?

SoundHound Eyes 25 Fortune 100 Brands: Can LivePerson Unlock Scale?

SOUN's LivePerson deal adds 25 Fortune 100 brands and unlocks a $500M revenue opportunity, but can it overcome integration risks and profitability pressures?

Nice (NICE) Declines More Than Market: Some Information for Investors

Nice (NICE) reached $115.02 at the closing of the latest trading day, reflecting a -2.1% change compared to its last close.

NICE Stock Analysis: Buy or Sell?

Investors are curious if this is a value stock or a value trap...

Here is What to Know Beyond Why Nice (NICE) is a Trending Stock

Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in Nice (NICE) Based on Bullish Wall Street Views?

Based on the average brokerage recommendation (ABR), Nice (NICE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Nice (NICE) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Nice (NICE) stood at $113.81, denoting a -2.3% move from the preceding trading day.

NiCE Named a Leader in the IDC MarketScape for Worldwide Agentic Contact Center-as-a-Service Platforms

NiCE (Nasdaq: NICE) today announced it has been positioned in the Leaders category in the IDC MarketScape: Worldwide Agentic Contact Centeras-a-Service Platforms 2026 Vendor Assessment (doc #US54117326, August 2026). We believe NiCE's position underscores the strength of its unified CX AI platform...

NICE Ltd. engages in the provision of enterprise software solutions and services. It operates through the following segments: Customer Engagement, and Financial Crime and Compliance Solutions. The Customer Engagement segment provides suites such as compliance and risk, workforce optimization, operational efficiency, customer experience, and sales and retention. The Financial Crime and Compliance Solutions segment includes embedded-AI solutions that identify risks and help prevent money laundering and fraud, as well as help ensure financial markets compliance in real-time. The company was founded on September 28, 1986 and is headquartered in Raanana, Israel.

NICE Ltd - ADR

NICE Stock Shot Up 9% Pre-Market Today – Investors Cheer Upbeat Q4, $600M Buyback Plan

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Cloud revenue led the way, rising 14% year-on-year to $608.3 million, and operating income reached $176.2 million, growing 14% year-on-year.</li><li>The CEO said in Q4, AI's annual recurring revenue increased 66% year-on-year.&nbsp;</li><li>The board also approved a new $600 million share repurchase authorization, lifting total remaining buyback capacity to roughly $1 billion.</li></ul>NiCE (NICE) on Thursday announced steady revenue growth in the fourth quarter (Q4), capping a year marked by expanding cloud demand and rising AI-driven sales.&nbsp;The customer experience software provider also authorized a $600 million share buyback program and unveiled fresh guidance for 2026.<h2 class="st-heading-2">Fourth-Quarter Performance</h2>In Q4, total revenue climbed to $786.5 million, reflecting a 9% year-on-year (YoY) increase with an adjusted earnings per share (EPS) of $3.24. While revenue exceeded analysts’ consensus estimate of $779.94 million, EPS was in line, according to Fiscal AI data.&nbsp;Cloud revenue led the way, rising 14% YoY to $608.3 million. Operating income reached $176.2 million, growing 14% YoY, while operating margin improved 100 basis points to 22.4%.Following the earnings announcement,&nbsp;<a href="https://stocktwits.com/symbol/NICE">NiCE stock</a> traded nearly 9% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment for the stock shifted to ‘extremely bullish’ from ‘bullish’ amid ‘high’ message volume.&nbsp;<blockquote>“In the fourth quarter 2025, AI ARR increased 66% year over year to $328 million, and AI was included in 100% of our new seven-figure CXone deals for the full year 2025, underscoring strong enterprise demand for our AI-native platform.”-Scott Russell, CEO, NiCE</blockquote><h2 class="st-heading-2">Capital Strategy, Buybacks And Outlook&nbsp;</h2>On February 18, the company secured a $300 million revolving credit facility arranged by JPMorgan Chase Bank, providing additional financial flexibility through early 2029. The board also approved a new $600 million share repurchase authorization, lifting total remaining buyback capacity to roughly $1 billion.NiCE projects first-quarter 2026 revenue between $755 million and $765 million, with adjusted EPS in the range of $2.45 to $2.55. For 2026, revenue is forecast between $3.17 billion and $3.19 billion, alongside adjusted EPS of $10.85 to $11.05.NICE stock has declined by over 445 in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sam-altman-urges-caution-on-superintelligent-ai-biggest-risks-remain-unknown/cZRjwW5R4wu">Sam Altman Urges Caution On Superintelligent AI – Says Biggest Risks Remain Unknown</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of US CRM software company NICE Ltd. is displayed on a smartphone.

In the fourth quarter, total revenue climbed to $786.5 million, reflecting a 9% year-on-year increase with an adjusted earnings per share of $3.24.

Global X Funds - Global X Artificial Intelligence & Technology ETF

NICE Systems Ltd.

Vanguard Information Technology ETF

Technology Select Sector SPDR Fund

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$115.22
Prev Close	$113.84
Open	$114.87
Dividend Yield	0.00%
50-Day Moving Average	$107.66
Beta	0.84
Avg. Volume	543,809.53
PE Ratio	16.45

52-Week High	$138.58
52-Week Low	$83.10
Market Capitalization	$6.65B
EPS (Annual)	$9.74
Price to Book	1.76
Revenue Per Employee	$308,411.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

NICE Fundamentals